.png){kind=icon}
.png){kind=icon}
Return
Cyclotherapy: exploiting cell-cycle decoupling for selective cancer cytotoxicity and normal-tissue protection
.png){kind=icon}
PRE
AI
I
R
D
G
DOI：10.1016/j.ctrv.2026.103172.png)
.png){kind=icon}
Original request for help.png){kind=icon}
Share.png){kind=icon}
Save
Abstract
En 中文
• Cyclotherapy transiently arrests normal cells to widen the therapeutic index. • CDK4/6 inhibition enables pharmacologic myeloprotection during chemotherapy. • Trilaciclib validates cyclotherapy clinically in small-cell lung cancer. • Tumor biology and scheduling determine cyclotherapy success or failure. • Cell-cycle–based toxicity classification may guide rational drug pairing.
Journal
IF:
10.5
Papers:
2.8K
Citations:
1.3W
Organization
Cited Papers